KalVista Pharmaceuticals (KALV) News Today $8.30 +0.05 (+0.61%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Barclays PLC raised its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 418.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 67,222 shares of the specialty pharmacJanuary 16, 2025 | marketbeat.comTD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy RecommendationJanuary 8, 2025 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD CowenTD Cowen started coverage on KalVista Pharmaceuticals in a research report on Tuesday. They issued a "buy" rating and a $30.00 price target on the stock.January 7, 2025 | marketbeat.comState Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)State Street Corp grew its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 68.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,271,609 shares of the spDecember 25, 2024 | marketbeat.comB of A Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy RecommendationDecember 19, 2024 | msn.comKalVista initiated with a Buy at BofADecember 18, 2024 | markets.businessinsider.comKalVista wins new Buy at BofA on potential of lead candidateDecember 18, 2024 | msn.comBank of America Initiates Coverage on KalVista Pharmaceuticals (NASDAQ:KALV)Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday. They issued a "buy" rating and a $22.00 target price for the company.December 18, 2024 | marketbeat.comKalVista Pharmaceuticals Appoints New COO Amid Strategic GrowthDecember 17, 2024 | markets.businessinsider.comKalVista Pharmaceuticals Appoints New COO Amid Strategic GrowthDecember 17, 2024 | markets.businessinsider.comKalVista Pharma Appoints Jeb Ledell As COODecember 16, 2024 | markets.businessinsider.comKalVista Appoints Jeb Ledell as Chief Operating OfficerDecember 16, 2024 | businesswire.comOptimistic Buy Rating for KalVista Pharmaceuticals: Strategic Financial Moves and Promising Drug Launch Bolster Market PotentialDecember 11, 2024 | markets.businessinsider.comBenjamin L. Palleiko Sells 7,627 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockDecember 10, 2024 | insidertrades.comWhat is HC Wainwright's Forecast for KALV FY2029 Earnings?KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at HC Wainwright lowered their FY2029 earnings estimates for KalVista Pharmaceuticals in a research note issued to investors on Friday, December 6th. HC Wainwright analyst A. Fein now anticipates that the specialtyDecember 9, 2024 | marketbeat.comKalVista Pharmaceuticals Set for Success with Sebetralstat’s Promising FDA Review and Strong Financial BackingDecember 6, 2024 | markets.businessinsider.comKalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday.December 6, 2024 | marketbeat.comKalVista Pharmaceuticals Reports Progress in HAE TreatmentDecember 6, 2024 | markets.businessinsider.com180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Readystate Asset Management LPReadystate Asset Management LP acquired a new position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 180,000 shares of the specDecember 5, 2024 | marketbeat.comKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateDecember 5, 2024 | businesswire.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Significant Increase in Short InterestKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 7,370,000 shares, an increase of 7.3% from the October 31st total of 6,870,000 shares. Based on an average trading volume of 415,400 shares, the days-to-cover ratio is currently 17.7 days.December 3, 2024 | marketbeat.comKalVista Pharmaceuticals' chief development officer sells $19,378 in stockNovember 29, 2024 | investing.comVestal Point Capital LP Has $46.32 Million Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Vestal Point Capital LP lifted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 73.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,000,000 shares of the specialty pharmaceutical comNovember 29, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,187 SharesNovember 28, 2024 | insidertrades.comKalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsNovember 26, 2024 | businesswire.comPaul K. Audhya Sells 8,077 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockNovember 21, 2024 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in StockKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 8,077 shares of the company's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the sale, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.November 20, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 14,400 SharesKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 14,400 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.November 20, 2024 | marketbeat.comFirst Turn Management LLC Sells 704,540 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)First Turn Management LLC trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 66.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 355,000 shares of the specialty pharmaceuNovember 19, 2024 | marketbeat.comKalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Passes Below Fifty Day Moving Average - Here's WhyKalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving Average - Here's What HappenedNovember 19, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Opus Genetics (IRD)November 13, 2024 | markets.businessinsider.comLeerink Partnrs Analysts Boost Earnings Estimates for KALVKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings estimates for KalVista Pharmaceuticals in a report released on Monday, November 4th. Leerink Partnrs analyst J. Schwartz now expects that the specialty pharmaceuticaNovember 7, 2024 | marketbeat.comKalVista prices $55M stock offeringNovember 5, 2024 | msn.comKalVista Pharmaceuticals Announces $60 Million Funding InitiativesNovember 5, 2024 | markets.businessinsider.comKalVista Pharmaceuticals: Strategic Financing and Market Potential Drive Buy RatingNovember 5, 2024 | markets.businessinsider.comKalVista Secures $184M Financing for Sebetralstat LaunchNovember 5, 2024 | finance.yahoo.comKalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - What's Next?KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up - Still a Buy?November 4, 2024 | marketbeat.comKalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionNovember 4, 2024 | businesswire.comEmerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Emerald Advisers LLC grew its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 29.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 835,988 shares of the specialty pharmaceutical company's stock after puNovember 3, 2024 | marketbeat.comKalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyOctober 28, 2024 | businesswire.comKalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)October 18, 2024 | finance.yahoo.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest UpdateKalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 6,510,000 shares, a growth of 13.8% from the September 15th total of 5,720,000 shares. Based on an average daily volume of 381,900 shares, the short-interest ratio is presently 17.0 days.October 16, 2024 | marketbeat.comAlnylam Pharma (ALNY) Receives a Buy from JefferiesOctober 11, 2024 | markets.businessinsider.comMarshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Marshall Wace LLP lowered its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 92.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,911 shares of the specialty pharmaceutical company's sOctober 10, 2024 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP trimmed its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 7.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 534,979 shares of the specialty pharmaceutical company's stock after selling 44,680 shaOctober 9, 2024 | marketbeat.comBuy Rating for KalVista Pharmaceuticals Based on Sebetralstat’s Market Potential and Patient Quality of Life ImprovementOctober 7, 2024 | markets.businessinsider.comKalVista Pharmaceuticals (NASDAQ:KALV) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday.October 7, 2024 | marketbeat.comKalVista Pharmaceuticals announces board election resultsOctober 6, 2024 | uk.investing.comKalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema ForumOctober 4, 2024 | finance.yahoo.comSusquehanna Fundamental Investments LLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)Susquehanna Fundamental Investments LLC increased its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 323.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,526 shares of the specialty pharmaceuticaOctober 3, 2024 | marketbeat.com Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address KALV Media Mentions By Week KALV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KALV News Sentiment▼1.680.44▲Average Medical News Sentiment KALV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KALV Articles This Week▼13▲KALV Articles Average Week Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies INDV News GLPG News GPCR News ARQT News EVO News IMCR News DYN News TVTX News VIR News SDGR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KALV) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts